XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 82 filers reported holding XENON PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $854,000 | -11.3% | 25,000 | 0.0% | 0.13% | -6.5% |
| Q2 2023 | $962,500 | +7.6% | 25,000 | 0.0% | 0.14% | +0.7% |
| Q1 2023 | $894,750 | -9.2% | 25,000 | 0.0% | 0.14% | -13.8% |
| Q4 2022 | $985,750 | +9.2% | 25,000 | 0.0% | 0.16% | +3.2% |
| Q3 2022 | $903,000 | +18.7% | 25,000 | 0.0% | 0.16% | +25.0% |
| Q2 2022 | $761,000 | -0.4% | 25,000 | 0.0% | 0.12% | +20.4% |
| Q1 2022 | $764,000 | -2.2% | 25,000 | 0.0% | 0.10% | +5.1% |
| Q4 2021 | $781,000 | +104.5% | 25,000 | 0.0% | 0.10% | +88.5% |
| Q3 2021 | $382,000 | -18.0% | 25,000 | 0.0% | 0.05% | -16.1% |
| Q2 2021 | $466,000 | +4.0% | 25,000 | 0.0% | 0.06% | -3.1% |
| Q1 2021 | $448,000 | +16.4% | 25,000 | 0.0% | 0.06% | +8.5% |
| Q4 2020 | $385,000 | +39.0% | 25,000 | 0.0% | 0.06% | +18.0% |
| Q3 2020 | $277,000 | -11.8% | 25,000 | 0.0% | 0.05% | -15.3% |
| Q2 2020 | $314,000 | +10.6% | 25,000 | 0.0% | 0.06% | -9.2% |
| Q1 2020 | $284,000 | -13.4% | 25,000 | 0.0% | 0.06% | +16.1% |
| Q4 2019 | $328,000 | +45.8% | 25,000 | 0.0% | 0.06% | +36.6% |
| Q3 2019 | $225,000 | -8.9% | 25,000 | 0.0% | 0.04% | -6.8% |
| Q2 2019 | $247,000 | -2.8% | 25,000 | 0.0% | 0.04% | -4.3% |
| Q1 2019 | $254,000 | +60.8% | 25,000 | 0.0% | 0.05% | +39.4% |
| Q4 2018 | $158,000 | -52.1% | 25,000 | 0.0% | 0.03% | -41.1% |
| Q3 2018 | $330,000 | -28.3% | 25,000 | -50.0% | 0.06% | -31.7% |
| Q2 2018 | $460,000 | +369.4% | 50,000 | +150.0% | 0.08% | +382.4% |
| Q1 2018 | $98,000 | +71.9% | 20,000 | 0.0% | 0.02% | +70.0% |
| Q4 2017 | $57,000 | -3.4% | 20,000 | 0.0% | 0.01% | -9.1% |
| Q3 2017 | $59,000 | -6.3% | 20,000 | 0.0% | 0.01% | -8.3% |
| Q2 2017 | $63,000 | -21.2% | 20,000 | 0.0% | 0.01% | -20.0% |
| Q1 2017 | $80,000 | -48.1% | 20,000 | 0.0% | 0.02% | -51.6% |
| Q4 2016 | $154,000 | -4.9% | 20,000 | 0.0% | 0.03% | -8.8% |
| Q3 2016 | $162,000 | +37.3% | 20,000 | 0.0% | 0.03% | +36.0% |
| Q2 2016 | $118,000 | -17.5% | 20,000 | 0.0% | 0.02% | -16.7% |
| Q1 2016 | $143,000 | -11.2% | 20,000 | 0.0% | 0.03% | -9.1% |
| Q4 2015 | $161,000 | -2.4% | 20,000 | 0.0% | 0.03% | -8.3% |
| Q3 2015 | $165,000 | -28.6% | 20,000 | 0.0% | 0.04% | -20.0% |
| Q2 2015 | $231,000 | – | 20,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |